Allergy Therapeutics (LON:AGY) Trading Down 14.3% - Time to Sell?

Key Points

• Shares fell 14.3% to GBX 9 on Tuesday (from a close of GBX 10.50) with 308,884 shares traded, about 7% above the average session volume.
• Recent results show a GBX (0.84) quarterly EPS, a negative net margin of 72.91% and analysts forecast a full-year EPS of -2.56; the stock metrics include a market cap of £647.5M and a P/E of -12.17.
• Allergy Therapeutics is a biotech focused on allergy immunotherapy vaccines with a pipeline for grass, tree and house dust mite vaccines and a peanut vaccine in pre-clinical development.

Shares of Allergy Therapeutics plc (LON:AGY - Get Free Report) fell 14.3% on Tuesday . The company traded as low as GBX 9 and last traded at GBX 9. 308,884 shares were traded during trading, an increase of 7% from the average session volume of 288,162 shares. The stock had previously closed at GBX 10.50.

Allergy Therapeutics Trading Down 2.6%

The company has a debt-to-equity ratio of -213.13, a quick ratio of 1.48 and a current ratio of 1.28. The firm has a market cap of £647.50 million, a price-to-earnings ratio of -12.17, a PEG ratio of -30.70 and a beta of 0.83. The business has a fifty day simple moving average of GBX 11.16 and a 200-day simple moving average of GBX 9.95.

Allergy Therapeutics (LON:AGY - Get Free Report) last announced its quarterly earnings results on Monday, February 16th. The company reported GBX (0.84) EPS for the quarter. Allergy Therapeutics had a negative net margin of 72.91% and a positive return on equity of 227.10%. As a group, equities analysts forecast that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.